HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 295/1/H39    most recent 00162.2008v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Kaul, D. K. Articles by Fabry, M. E. Search for Related Content PubMed PubMed Citation Articles by Kaul, D. K. Articles by Fabry, M. E.

Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress

Division of Hematology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York

Submitted 14 February 2008 ; accepted in final form 25 April 2008

In sickle cell disease, nitric oxide (NO) depletion by cell-free plasma hemoglobin and/or oxygen radicals is associated with arginine deficiency, impaired NO bioavailability, and chronic oxidative stress. In transgenic-knockout sickle (BERK) mice that express exclusively human - and β^S-globins, reduced NO bioavailability is associated with induction of non-NO vasodilator enzyme, cyclooxygenase (COX)-2, and impaired NO-mediated vascular reactivity. We hypothesized that enhanced NO bioavailability in sickle mice will abate activity of non-NO vasodilators, improve vascular reactivity, decrease hemolysis, and reduce oxidative stress. Arginine treatment of BERK mice (5% arginine in mouse chow for 15 days) significantly reduced expression of non-NO vasodilators COX-2 and heme oxygenase-1. The decreased COX-2 expression resulted in reduced prostaglandin E₂ (PGE₂) levels. The reduced expression of non-NO vasodilators was associated with significantly decreased arteriolar dilation and markedly improved NO-mediated vascular reactivity. Arginine markedly decreased hemolysis and oxidative stress and enhanced NO bioavailability. Importantly, arteriolar diameter response to a NO donor (sodium nitroprusside) was strongly correlated with hemolytic rate (and nitrotyrosine formation), suggesting that the improved microvascular function was a response to reduced hemolysis. These results provide a strong rationale for therapeutic use of arginine in sickle cell disease and other hemolytic diseases.

sickle cell disease; microvascular regulation; vasoreactivity

This article has been cited by other articles:

				N. D. Kanika, M. Tar, Y. Tong, D. S. R. Kuppam, A. Melman, and K. P. Davies The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway Am J Physiol Cell Physiol, October 1, 2009; 297(4): C916 - C927. [Abstract] [Full Text] [PDF]

				M. L. Krajewski, L. L. Hsu, and M. T. Gladwin The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H4 - H7. [Full Text] [PDF]

				C. R. Morris Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia Hematology, January 1, 2008; 2008(1): 177 - 185. [Abstract] [Full Text] [PDF]

				G. J. Kato Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I Hematology, January 1, 2008; 2008(1): 186 - 192. [Abstract] [Full Text] [PDF]